Updated information on COVID-19 and Flu: Restricted visitation is now in effect
Sub Category
Rare Tumor
Study Name
S1609/DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in rare tumors. This Clinical Trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab may interfere with the ability of tumor cells to grow and spread
Principal Investigator
Gordan Srkalovic, MD, PhD
Study Information
Contact for Questions
Nurse - Tracy 517-364-2835

Site view: at a glance